Atea Pharmaceuticals (AVIR) investor relations material

Executive summary

• Two pivotal Phase 3 HCV trials (C-BEYOND and C-FORWARD) are progressing, with topline results expected mid-2026 and year-end 2026, and NDA submission targeted for Q1–March 2027.

• Enrollment for both Phase 3 HCV trials is nearly complete globally, with over 1,760 patients enrolled and stratification by cirrhosis status, genotype, and HIV co-infection.

• The antiviral pipeline expanded to include AT-587 for chronic hepatitis E, targeting immunocompromised patients with no approved therapies; Phase 1 initiation planned for mid-2026.

• No products approved or commercial revenue to date; all resources directed toward R&D and clinical advancement, with commercial launch preparations underway.

• Strong financial position with $256 million in cash, cash equivalents, and marketable securities as of March 31, 2026, supporting operations through 2027.

Financial highlights

• Net loss for Q1 2026 was $45.4 million, compared to $34.3 million in Q1 2025, driven by increased R&D expenses for HCV and HEV programs.

• Operating expenses rose to $48.0 million from $39.0 million year-over-year, primarily due to higher external spend on clinical programs.

• Cash, cash equivalents, and marketable securities totaled $256.0 million at March 31, 2026, down from $301.8 million at year-end 2025.

• General and administrative expenses decreased due to lower salaries, stock-based compensation, and professional fees.

• No revenue generated; interest income and other, net, decreased to $2.6 million from $5.0 million year-over-year.

Outlook and guidance

• Cash runway projected to extend through 2027, enabling completion of Phase 3 HCV trials, advancement of HEV program, and commercial readiness.

• Topline results for C-BEYOND expected mid-2026 and for C-FORWARD by year-end 2026; NDA submission for HCV regimen anticipated in Q1–March 2027.

• Phase 1 clinical program for AT-587 in HEV anticipated to begin mid-2026, with proof-of-concept study planned around year-end.

• No product revenue anticipated until at least 2027, pending successful clinical results and regulatory approvals.

• Open to strategic transactions and collaborations to maximize shareholder value.